NASDAQ:ABOS Acumen Pharmaceuticals - ABOS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.87 -0.14 (-3.49%) (As of 03/17/2023 06:55 PM ET) Add Compare Share Share Today's Range$3.85▼$4.0950-Day Range$3.87▼$6.6552-Week Range$3.02▼$10.97Volume127,400 shsAverage Volume81,902 shsMarket Capitalization$156.74 millionP/E RatioN/ADividend YieldN/APrice Target$17.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Acumen Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside356.5% Upside$17.67 Price TargetShort InterestBearish2.29% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.75Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.01) to ($1.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.01 out of 5 starsMedical Sector543rd out of 983 stocksBiological Products, Except Diagnostic Industry98th out of 161 stocks 3.5 Analyst's Opinion Consensus RatingAcumen Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.67, Acumen Pharmaceuticals has a forecasted upside of 356.5% from its current price of $3.87.Amount of Analyst CoverageAcumen Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.29% of the float of Acumen Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcumen Pharmaceuticals has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Acumen Pharmaceuticals has recently increased by 6.21%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAcumen Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcumen Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABOS. Previous Next 2.6 News and Social Media Coverage News SentimentAcumen Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Acumen Pharmaceuticals this week, compared to 1 article on an average week.MarketBeat FollowsOnly 3 people have added Acumen Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acumen Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.70% of the stock of Acumen Pharmaceuticals is held by insiders.Percentage Held by Institutions67.92% of the stock of Acumen Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Acumen Pharmaceuticals are expected to decrease in the coming year, from ($1.01) to ($1.38) per share.Price to Book Value per Share RatioAcumen Pharmaceuticals has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Acumen Pharmaceuticals (NASDAQ:ABOS) StockAcumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Read More Receive ABOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ABOS Stock News HeadlinesMarch 17, 2023 | americanbankingnews.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Significant Growth in Short InterestMarch 8, 2023 | finance.yahoo.comAcumen Pharmaceuticals to Participate in the Needham Neuroscience ForumMarch 20, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.February 15, 2023 | finance.yahoo.comAcumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth PlansFebruary 13, 2023 | finance.yahoo.comAcumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients with Early Alzheimer’s DiseaseJanuary 18, 2023 | seekingalpha.comABOS Acumen Pharmaceuticals, Inc.January 6, 2023 | finance.yahoo.comIs Novo Nordisk (NVO) Stock Outpacing Its Medical Peers This Year?January 4, 2023 | finance.yahoo.comAcumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of DirectorsMarch 20, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.December 29, 2022 | finance.yahoo.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2022 Earnings Call TranscriptDecember 6, 2022 | benzinga.comShort Volatility Alert: Acumen PharmaceuticalNovember 19, 2022 | finanznachrichten.deAcumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business HighlightsNovember 15, 2022 | seekingalpha.comAcumen Pharmaceuticals, Inc. (ABOS) CEO Daniel O'Connell on Q3 2022 Results - Earnings Call TranscriptNovember 15, 2022 | finance.yahoo.comAcumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business HighlightsNovember 12, 2022 | msn.comEarnings Preview: Acumen PharmaceuticalsNovember 9, 2022 | finance.yahoo.comAcumen Pharmaceuticals to Participate in the Stifel Healthcare ConferenceNovember 8, 2022 | finance.yahoo.comAcumen Pharmaceuticals to Report Third Quarter 2022 Financial Results on Nov. 14, 2022November 1, 2022 | finance.yahoo.comAcumen Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193, an Anti-Amyloid Beta Oligomer Antibody for Alzheimer’s DiseaseOctober 24, 2022 | finance.yahoo.comAcumen’s ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted FDA Fast Track Designation for Alzheimer's DiseaseOctober 13, 2022 | marketwatch.comThinking about buying stock in Acumen Pharmaceuticals, Delta Air Lines, Blue Apron, United Airlines, or SeaSpine Holdings?October 12, 2022 | msn.comHow Is The Market Feeling About Acumen Pharmaceuticals?September 28, 2022 | seekingalpha.comAcumen Pharma at 11-month high on rivals’ Alzheimer’s dataSeptember 8, 2022 | finance.yahoo.comWe Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business GrowthAugust 16, 2022 | seekingalpha.comAcumen Pharmaceuticals, Inc. (ABOS) CEO Daniel O'Connell on Q2 2022 Results - Earnings Call TranscriptAugust 15, 2022 | finance.yahoo.comAcumen Pharmaceuticals Reports Financial Results for Second Quarter 2022 and Business HighlightsAugust 8, 2022 | finance.yahoo.comAcumen Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 15, 2022August 1, 2022 | finance.yahoo.comAcumen presents poster describing method to standardize amyloid beta oligomer assays supporting therapeutic development for early Alzheimer’s diseaseSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ABOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ABOS Company Calendar Last Earnings11/14/2021Today3/20/2023Next Earnings (Estimated)3/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ABOS CUSIPN/A CIK1576885 Webwww.acumenpharm.com Phone434-297-1000FaxN/AEmployees14Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.67 High Stock Price Forecast$22.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+356.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-100,610,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-18.16% Return on Assets-17.72% Debt Debt-to-Equity RatioN/A Current Ratio30.63 Quick Ratio30.63 Sales & Book Value Annual Sales$1.44 million Price / Sales108.84 Cash FlowN/A Price / Cash FlowN/A Book Value$5.56 per share Price / Book0.70Miscellaneous Outstanding Shares40,500,000Free Float38,599,000Market Cap$156.74 million OptionableNot Optionable Beta-1.48 Key ExecutivesMr. Daniel J. O'Connell M.B.A. (Age 52)CEO, Pres & Director Comp: $801.62kMr. Matt ZugaCFO, Chief Bus. Officer & Corp. Sec.Dr. Eric Siemers M.D. (Age 68)Chief Medical Officer Comp: $460.64kMr. Russell Barton M.S. (Age 64)Chief Operating Officer Mr. Derek M. Meisner Esq. (Age 52)J.D., Chief Legal Officer Ms. Robyn Moxon M.A.Mang. of Corp. & Clinical CommunicationsMs. Julie BockenstetteExec. VP & Head of HRMs. Siew Tin Gan M.S.Assistant VP & Head of Clinical OperationsMs. Janice HitchcockVP & Head of Regulatory AffairsMs. Liean Schenck M.S.VP & Head of CMCMore ExecutivesKey CompetitorsInvivydNASDAQ:IVVDJATT AcquisitionNYSE:JATTIkena OncologyNASDAQ:IKNAAdaptimmune TherapeuticsNASDAQ:ADAPSorrento TherapeuticsNASDAQ:SRNEView All CompetitorsInstitutional OwnershipSilverarc Capital Management LLCSold 124,885 shares on 2/15/2023Ownership: 0.729%Atom Investors LPBought 62,441 shares on 2/15/2023Ownership: 0.154%Morgan StanleyBought 6,770 shares on 2/15/2023Ownership: 0.063%Man Group plcBought 21,529 shares on 2/15/2023Ownership: 0.053%Jane Street Group LLCBought 10,198 shares on 2/15/2023Ownership: 0.025%View All Institutional Transactions ABOS Stock - Frequently Asked Questions Should I buy or sell Acumen Pharmaceuticals stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acumen Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ABOS shares. View ABOS analyst ratings or view top-rated stocks. What is Acumen Pharmaceuticals' stock price forecast for 2023? 3 analysts have issued 1 year target prices for Acumen Pharmaceuticals' stock. Their ABOS share price forecasts range from $15.00 to $22.00. On average, they expect the company's stock price to reach $17.67 in the next twelve months. This suggests a possible upside of 356.5% from the stock's current price. View analysts price targets for ABOS or view top-rated stocks among Wall Street analysts. How have ABOS shares performed in 2023? Acumen Pharmaceuticals' stock was trading at $5.40 at the beginning of 2023. Since then, ABOS shares have decreased by 28.3% and is now trading at $3.87. View the best growth stocks for 2023 here. Are investors shorting Acumen Pharmaceuticals? Acumen Pharmaceuticals saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 634,100 shares, an increase of 6.2% from the February 13th total of 597,000 shares. Based on an average trading volume of 81,300 shares, the short-interest ratio is currently 7.8 days. Approximately 2.3% of the shares of the stock are short sold. View Acumen Pharmaceuticals' Short Interest. When is Acumen Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023. View our ABOS earnings forecast. How were Acumen Pharmaceuticals' earnings last quarter? Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) posted its quarterly earnings data on Sunday, November, 14th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.07. When did Acumen Pharmaceuticals IPO? (ABOS) raised $125 million in an IPO on Thursday, July 1st 2021. The company issued 8,333,333 shares at $14.00-$16.00 per share. What is Acumen Pharmaceuticals' stock symbol? Acumen Pharmaceuticals trades on the NASDAQ under the ticker symbol "ABOS." Who are Acumen Pharmaceuticals' major shareholders? Acumen Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (1.64%), Driehaus Capital Management LLC (1.39%), Pathstone Family Office LLC (1.31%), Silverarc Capital Management LLC (0.73%), Geode Capital Management LLC (0.41%) and WMS Partners LLC (0.24%). Insiders that own company stock include John A Stalfort III, Marc Benioff, Nathan B Fountain, Paul B Manning and Sands Capital Global Venture F. View institutional ownership trends. How do I buy shares of Acumen Pharmaceuticals? Shares of ABOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Acumen Pharmaceuticals' stock price today? One share of ABOS stock can currently be purchased for approximately $3.87. How much money does Acumen Pharmaceuticals make? Acumen Pharmaceuticals (NASDAQ:ABOS) has a market capitalization of $156.74 million and generates $1.44 million in revenue each year. How can I contact Acumen Pharmaceuticals? The official website for the company is www.acumenpharm.com. The company can be reached via phone at 434-297-1000 or via email at investors@acumenpharm.com. This page (NASDAQ:ABOS) was last updated on 3/20/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.